(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 45.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.83%.
Geron's revenue in 2025 is $164,447,000.On average, 4 Wall Street analysts forecast GERN's revenue for 2025 to be $127,304,822,610, with the lowest GERN revenue forecast at $122,116,467,772, and the highest GERN revenue forecast at $131,878,128,989. On average, 4 Wall Street analysts forecast GERN's revenue for 2026 to be $202,849,234,138, with the lowest GERN revenue forecast at $186,428,588,731, and the highest GERN revenue forecast at $219,733,079,941.
In 2027, GERN is forecast to generate $332,332,247,035 in revenue, with the lowest revenue forecast at $305,310,309,943 and the highest revenue forecast at $373,826,963,412.